Premier Biosoft

PREMIER Biosoft
Private
Founded 1994
Headquarters Palo Alto, California
Key people
Arun Apte (CEO)
Website www.premierbiosoft.com

PREMIER Biosoft (PB) is a California, United States based bioinformatics company. The company specializes in developing software for use in life science research. In addition to developing software products, the company offers consultancy for bioinformatics projects.[1]

Company background

PREMIER Biosoft, established in 1994, is one of the earliest bioinformatics company, founded by Arun Apte and Kay Brown with a mission to serve the life science research labs all over the world. The mission statement for PB reads as follows: “Accelerating Research in Life Sciences”. The company serves research labs, pharmaceuticals, core facilities and biotechnology companies with its products. The company's first product, Primer Premier, was authored over 17 years ago, for designing PCR assays.

Products and services

After the launch of Primer Premier the company released SimVector, a plasmid drawing and cloning simulation tool, and Array Designer, for designing microarray probes.

The trend in the PCR market was soon shifting towards a new and powerful technique called real time PCR. PREMIER Biosoft caught up early and authored Beacon Designer™, supporting the most popular real time PCR chemistries The company later came out with a pathogen detection system called AlleleID® with support for real time PCR and microarray probe design for designing cross species, species specific, intron-exon spanning assays and splice variant microarrays.

The company has ventured into proteomics, glycomics and lipidomics research with the launch of Xpression Primer (tagged primer design tool), SimGlycan® (MS/MS data analysis tool) and SimLipid (lipid characterization tool). The company's latest offerings, MALDIVision for MALDI IMS, analyzes and visualizes ion distribution in tissues and PrimerPlex for xMAP, designs oligos for multiplex systems.

References

This article is issued from Wikipedia - version of the 11/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.